Access

You are not currently logged in.

Access your personal account or get JSTOR access through your library or other institution:

login

Log in to your personal account or through your institution.

Drug Discovery and Natural Products: End of an Era or an Endless Frontier?

Jesse W.-H. Li and John C. Vederas
Science
New Series, Vol. 325, No. 5937 (Jul. 10, 2009), pp. 161-165
Stable URL: http://www.jstor.org/stable/20536593
Page Count: 5
  • More info
  • Cite this Item
Preview not available
Preview not available

Abstract

Historically, the majority of new drugs have been generated from natural products (secondary metabolites) and from compounds derived from natural products. During the past 15 years, pharmaceutical industry research into natural products has declined, in part because of an emphasis on high-throughput screening of synthetic libraries. Currently there is substantial decline in new drug approvals and impending loss of patent protection for important medicines. However, untapped biological resources, "smart screening" methods, robotic separation with structural analysis, metabolic engineering, and synthetic biology offer exciting technologies for new natural product drug discovery. Advances in rapid genetic sequencing, coupled with manipulation of biosynthetic pathways, may provide a vast resource for the future discovery of pharmaceutical agents.

Page Thumbnails

  • Thumbnail: Page 
161
    161
  • Thumbnail: Page 
162
    162
  • Thumbnail: Page 
163
    163
  • Thumbnail: Page 
164
    164
  • Thumbnail: Page 
165
    165